Li Hang, Bai Lin
Institute of Laboratory Animal Science, National Human Diseases Animal Model Resource Center, CAMS & PUMC, National Center of Technology Innovation for Animal Model, Chao-yang District, Beijing, 100021, China.
Stem Cell Res Ther. 2025 Jul 26;16(1):401. doi: 10.1186/s13287-025-04318-1.
Mesenchymal stem/stromal cells (MSCs) and their exosomes (MSC-Exos) have great potential for tissue repair and regenerative medicine, which can improve the symptoms and prognosis of aging-related diseases and potentially slow the aging process through multiple pathways. This comprehensive review summarizes the characterization of MSCs and MSC-Exos from various tissue sources and their applications in treating diseases associated with aging, such as premature ovarian failure (POF), Alzheimer's disease (AD), atherosclerosis (AS), and osteoporosis (OP). MSCs exert therapeutic effects through multiple mechanisms, including differentiation into various cell types, secretion of bioactive molecules, and immune response regulation. MSC-Exos, which contain a diverse array of proteins, miRNAs, and other biomolecules, can deliver MSC-derived bioinformatics to target cells and demonstrate comparable therapeutic benefits to MSCs. This review highlights the signaling pathways and molecular mechanisms underlying the therapeutic efficacy of MSCs and MSC-Exos in age-related diseases, and further discusses the importance of MSC and MSC-Exo tissue source selection for specific disease applications and the potential of combination therapies and preconditioning strategies to enhance their therapeutic outcomes. Despite promising preclinical and clinical results, challenges such as uneven distribution, in vivo environmental maladaptation, apoptosis, and immune responses need to be addressed before widespread clinical application. Future research requires multidisciplinary collaboration to further elucidate the mechanisms of action and develop optimized therapeutic strategies for the prevention and treatment of age-related pathologies using MSCs and MSC-Exos.
间充质干/基质细胞(MSCs)及其外泌体(MSC-Exos)在组织修复和再生医学方面具有巨大潜力,它们可以改善与衰老相关疾病的症状和预后,并有可能通过多种途径减缓衰老过程。这篇综述总结了来自不同组织来源的MSCs和MSC-Exos的特性,以及它们在治疗与衰老相关疾病中的应用,如卵巢早衰(POF)、阿尔茨海默病(AD)、动脉粥样硬化(AS)和骨质疏松症(OP)。MSCs通过多种机制发挥治疗作用,包括分化为各种细胞类型、分泌生物活性分子以及调节免疫反应。MSC-Exos包含多种蛋白质、miRNA和其他生物分子,可将MSC衍生的生物信息传递给靶细胞,并显示出与MSCs相当的治疗效果。本综述强调了MSCs和MSC-Exos在年龄相关疾病治疗效果背后的信号通路和分子机制,并进一步讨论了针对特定疾病应用选择MSC和MSC-Exo组织来源的重要性,以及联合治疗和预处理策略提高其治疗效果的潜力。尽管临床前和临床结果很有前景,但在广泛临床应用之前,仍需解决诸如分布不均、体内环境不适应、细胞凋亡和免疫反应等挑战。未来的研究需要多学科合作,以进一步阐明作用机制,并开发优化的治疗策略,使用MSCs和MSC-Exos预防和治疗与年龄相关的疾病。